PMID- 34277062
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210720
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 13
IP  - 6
DP  - 2021 Jun
TI  - A narrative review of advances in treatment and survival prognosis of 
      HER2-positive malignant lung cancers.
PG  - 3708-3720
LID - 10.21037/jtd-20-3265 [doi]
AB  - Human epidermal growth factor receptor 2 (HER2), as a receptor tyrosine kinase of 
      EGF receptor family, whose mutation is often associated with even if less 
      frequency but poor prognosis and shorter survival in pulmonary malignant tumor. 
      HER2 status include mutation, overexpression, amplification and also some rare 
      genotypes, detected by next generation sequencing (NGS), immunohistochemistry 
      (IHC), and also fluorescence in situ hybridization (FISH). Different genotypes 
      represent different therapeutic targets and indicate different clinical prognosis 
      concluded by previous studies. Unfortunately, no standard guidelines for 
      first-line treatment are widely recognized, and current therapeutic schedules 
      include chemotherapy, radiotherapy, targeted therapy, and immunotherapy. 
      Especially for patients with advanced metastasis, chemotherapy is based as a 
      systemic therapy using studies of breast cancer or EGFR-positive lung 
      adenocarcinoma as a template. Studies already explored treatment including EGFR 
      tyrosine kinase inhibitors (TKIs) such as gefitinib and afatinib, and also 
      trastuzumab and its conjugation like HER2-targeted antibody-drug conjugate 
      trastuzumab emtansine (T-DM1) and conjugate trastuzumab deruxtecan (T-DXd). Also, 
      he researches explored combination therapy with chemotherapy and TKIs or 
      monoclonal antibodies. This review describes commonly used therapies for 
      HER2-positive/HER2-overexpression patients and general relationship between 
      genotypes of HER2, drug selection and final prognosis in order to provide 
      suggestions for future diagnosis and treatment.
CI  - 2021 Journal of Thoracic Disease. All rights reserved.
FAU - Wu, Ranpu
AU  - Wu R
AD  - Department of Respiratory and Critical Care Medicine, Jinling Hospital, Southeast 
      University of Medicine, Nanjing, China.
FAU - Yuan, Bingxiao
AU  - Yuan B
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Medical School of Nanjing Medical University, Nanjing, China.
FAU - Li, Chuling
AU  - Li C
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Medical School of Nanjing Medical University, Nanjing, China.
FAU - Wang, Zimu
AU  - Wang Z
AD  - Department of Respiratory Medicine, Jinling Hospital, Nanjing University School 
      of Medicine, Nanjing, China.
FAU - Song, Yong
AU  - Song Y
AD  - Department of Respiratory and Critical Care Medicine, Jinling Hospital, Southeast 
      University of Medicine, Nanjing, China.
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Medical School of Nanjing Medical University, Nanjing, China.
FAU - Liu, Hongbing
AU  - Liu H
AD  - Department of Respiratory and Critical Care Medicine, Jinling Hospital, Southeast 
      University of Medicine, Nanjing, China.
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Medical School of Nanjing Medical University, Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC8264687
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - chemotherapy
OT  - human epidermal growth factor receptor 2 (HER2)
OT  - trastuzumab
OT  - tyrosine kinase inhibitors (TKIs)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/jtd-20-3265). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/07/20 06:00
MHDA- 2021/07/20 06:01
PMCR- 2021/06/01
CRDT- 2021/07/19 05:56
PHST- 2020/11/09 00:00 [received]
PHST- 2021/04/14 00:00 [accepted]
PHST- 2021/07/19 05:56 [entrez]
PHST- 2021/07/20 06:00 [pubmed]
PHST- 2021/07/20 06:01 [medline]
PHST- 2021/06/01 00:00 [pmc-release]
AID - jtd-13-06-3708 [pii]
AID - 10.21037/jtd-20-3265 [doi]
PST - ppublish
SO  - J Thorac Dis. 2021 Jun;13(6):3708-3720. doi: 10.21037/jtd-20-3265.